Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

• DOI: 10.1007/s00508-023-02221-4
• Publication Date: 2023-06-08T03:26:22Z
• Authors: Hermann Toplak; Aikaterini Bilitou; Hannes Alber; Johann Auer; Martin Clodi; Christoph Ebenbic...; Evelyn Fließer-Gö...; Carmen Gelsinger; Ursula Hanusch; Bernhard Ludvik; Thomas Maca; Andreas Schober; Reinhard Sock; Walter S. Speidl; Thomas M. Stulnig; Raimund Weitgasser; Andreas Zirlik; Marina Koch; Sebastian Wienerr...; Sorrel E. Wolowacz; Françoise Diamand; Alberico L. Catapano
• Keywords: Ezetimibe

The low-density lipoprotein cholesterol goals in the 2019 European Society of Cardiology/European Atherosclerosis dyslipidaemia guidelines necessitate greater use combination therapies. We describe a real-world cohort patients Austria and simulate addition oral bempedoic acid ezetimibe to estimate proportion reaching goals.Patients at high or very cardiovascular risk on lipid-lowering treatments (excluding proprotein convertase subtilisin/kexin type 9 inhibitors) from Austrian observational SANTORINI study were included using specific criteria. For not their risk-based baseline, (if already received) subsequently was simulated Monte Carlo simulation.A (N = 144) with mean 76.4 mg/dL, 94% (n 135) statins 24% 35) monotherapy combination, used simulation. Only 36% goal 52). Sequential simulation (where applicable) increased 69% 100), decrease mg/dL baseline 57.7 overall.The data suggest that high-risk remain below guideline-recommended goals. Optimising after pathway could result substantially more attaining goals, likely additional health benefits.